Muscle Loss During First-Line Chemotherapy Impairs Survival in Advanced Pancreatic Cancer Despite Adapted Physical Activity.

Date publication

janvier 2025

Journal

Journal of cachexia, sarcopenia and muscle

Auteurs

Membres identifiés du Cancéropôle Est :
Dr VERNEREY Dewi , Mme HENRIQUES Julie

Tous les auteurs :
Parent P, Pigneur F, Hilmi M, Carnot A, Garcia Larnicol ML, Vernerey D, Luciani A, Hammel P, Henriques J, Neuzillet C, Turpin A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39825571

Résumé

Advanced pancreatic ductal adenocarcinoma (aPDAC) is often accompanied by significant muscle mass loss, contributing to poor prognosis. SarcAPACaP, an ancillary study of the GERCOR-APACaP phase III trial, evaluated the role of adapted physical activity (APA) in aPDAC Western patients receiving first-line chemotherapy. The study aimed to assess (1) the potential impact of computed tomography (CT)-quantified muscle mass before and during treatments on health-related quality of life (HRQoL) and overall survival (OS) and (2) the role of APA in mitigating muscle mass loss.

Mots clés

CT scan, adapted physical activity, muscular mass loss, pancreatic cancer, quality of life, sarcopenia

Référence

J Cachexia Sarcopenia Muscle. 2025 01 17;: